Malignant melanoma

Indication for Dacarbazine

Population group: Suitable for both men and women, only adults (18 years old or older)

For this indication, competent medicine agencies globally authorize below treatments:

200-250 mg/m² once daily for 5 days

Route of admnistration

Intravenous

Defined daily dose

200 - 250 mg per m² of body surface area (BSA)

Dosage regimen

From 200 To 250 mg per m² of body surface area (BSA) once every day for 5 day(s)

Detailed description

Dacarbazine can be administered as single agent in doses of 200 to 250 mg/m² body surface area/day as an i.v. injection for 5 days every 3 weeks.

As an alternative to an intravenous bolus injection dacarbazine can be administered as a short-term infusion (over 15-30 minutes).

Dosage considerations

Doses up to 200 mg/m² may be given as a slow intravenous injection. Larger doses (ranging from 200 to 850 mg/m²) should be administered as an i.v. infusion over 15-30 minutes.

850 mg/m² once every 3 weeks

Route of admnistration

Intravenous

Defined daily dose

850 - 850 mg per m² of body surface area (BSA)

Dosage regimen

From 850 To 850 mg per m² of body surface area (BSA) once every 21 day(s)

Detailed description

It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as intravenous infusion.

Dosage considerations

Doses up to 200 mg/m² may be given as a slow intravenous injection. Larger doses (ranging from 200 to 850 mg/m²) should be administered as an i.v. infusion over 15-30 minutes.

Active ingredient

Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis.

Read more about Dacarbazine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner